419 related articles for article (PubMed ID: 9702435)
1. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
[TBL] [Abstract][Full Text] [Related]
2. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
[TBL] [Abstract][Full Text] [Related]
4. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
[TBL] [Abstract][Full Text] [Related]
5. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
Finer N; James WP; Kopelman PG; Lean ME; Williams G
Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
Hanefeld M; Sachse G
Diabetes Obes Metab; 2002 Nov; 4(6):415-23. PubMed ID: 12406041
[TBL] [Abstract][Full Text] [Related]
8. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
9. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
10. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
Jacob S; Rabbia M; Meier MK; Hauptman J
Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
Berne C;
Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
[TBL] [Abstract][Full Text] [Related]
12. Treatment with orlistat reduces cardiovascular risk in obese patients.
Zavoral JH
J Hypertens; 1998 Dec; 16(12 Pt 2):2013-7. PubMed ID: 9886891
[TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
[TBL] [Abstract][Full Text] [Related]
14. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
[TBL] [Abstract][Full Text] [Related]
15. A one-year trial to assess the value of orlistat in the management of obesity.
James WP; Avenell A; Broom J; Whitehead J
Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
[TBL] [Abstract][Full Text] [Related]
16. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
17. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
18. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
[TBL] [Abstract][Full Text] [Related]
19. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.
Shi YF; Pan CY; Hill J; Gao Y
Diabet Med; 2005 Dec; 22(12):1737-43. PubMed ID: 16401321
[TBL] [Abstract][Full Text] [Related]
20. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.
Kelley DE; Kuller LH; McKolanis TM; Harper P; Mancino J; Kalhan S
Diabetes Care; 2004 Jan; 27(1):33-40. PubMed ID: 14693963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
